Dhanvantri Jeevan Rekha Limited (531043) Fair Value & Analysis
Other · IN · Market cap ₹24.8M
Fair value as of: Jul 4, 2026
From 24 valuation models · updated today
Share price +32.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹16.75 – ₹35.85 · fair‑value band ₹12.44 – ₹20.74 · the ₹26.45 price screens above the ₹16.59 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Dhanvantri Jeevan Rekha Limited (531043) currently trades at ₹26.45, while our model-based Fair Value estimate is ₹16.59 — implying the stock looks roughly 37.3% overvalued today. We read business quality at 61/100 (solid quality), in the Other sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Dhanvantri Jeevan Rekha Limited generated revenue of ₹148M at a net margin of -8.9%. Revenue declined 73.7% year over year. The stock trades on a trailing P/E of 21.3. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Dhanvantri Jeevan Rekha Limited provides medical and health care services in India. The company operates the multi-specialty Dhanvantri hospital in Meerut. Its Dhanvantri Hospital offers diagnostic and therapeutic services, including cardiology, neurology, respiratory medicine, gastroenterology, gastro surgery, neuro surgery, orthopedic surgery, urology, oral and maxillofaccial surgery, oncology, otorhinolaryngology, pathology, rehabilitation program, and other diagnostic services. The company also operates intensive coronary care units and intensive care units. In addition, it offers services for various breast problems, such as mastalgias, mastopathies, breast lumps, and breast cancer, as well as screening for early breast cancers and training for self-examinations. Dhanvantri Jeevan Rekha Limited was founded in 1993 and is based in Meerut, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Dhanvantri Jeevan Rekha Limited reported revenue of ₹259M in FY2026 versus ₹168M in FY2022, a compound +11.4%/yr. Reported net income was ₹4.0M in FY2026, compounding −5.0%/yr from FY2022.
Is 531043 fairly valued? → Check now
Similar stocks
6 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| There MOH | €521.90 | €269.92 | -48% |
| Sony Corporation SON1 | €17.58 | €39.38 | +124% |
| Federal Home Loan Mortgage Corporation FREJO | $16.84 | $64.93 | +286% |
| 533278 533278 | ₹438.60 | ₹720.31 | +64% |
| Nestl?? India Limited 500790 | ₹1,459 | ₹279.60 | -81% |
| 540376 540376 | ₹3,993 | ₹1,806 | -55% |
Explore undervalued stocks
Frequently asked questions
Is Dhanvantri Jeevan Rekha Limited (531043) undervalued?
What is the fair value of 531043?
What is the quality score of 531043?
What is the revenue of Dhanvantri Jeevan Rekha Limited (531043)?
What is the net profit margin of 531043?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.